Alcohol Addiction Treatment

vivitrol

Alcoholism Treatment with Vivitrol

Vivitrol is prescription medication that is given as an injection by a healthcare provider, once a month or every 4 weeks. It is the most effective medication currently used for alcoholism treatment.

Vivitrol is an injectable time released form of naltrexone that is taken once a month. Vivitrol acts on the brain's receptors for pleasure, blocking the receptor's ability to gain any reaction from chemicals such as alcohol. This is theorized to reduce an alcoholic's craving for alcohol by slowly releasing the drug over the course of a month. Vivitrol is in the Opioid family of drugs, so a patient should not take any opioid (legal or illegal) with Vivitrol. Vivitrol alone can't cure a person of alcoholism. It's meant to be used as part of a multi-layered treatment plan, including counseling, regular exercise and perhaps other psychotropic medications to help regulate mood or reduce impulsivity.

Counseling plus anti-craving medications (such as Naltrexone) is the most effective treatment available today. Competent, professional, one-to-one counseling that will free you from the problems causing your drinking. Anti-craving medications will allow you to focus on your issues, free from cravings for the first time in years.

INSynergy provides monthly Vivitrol injections for those patients unable to receive this medication through their local physician. The staff psychiatrist will review your appropriateness for the medication, consult with your family physician and sign off on your suitability for the medication. The staff nurse will administer the medication and other medical staff will review possible side effects. All patients are encouraged to report any side effects to our staff MD.

Learn More about the Vivitrol Treatment

INSynergy is an approved provider of Vivitrol, and we serve clients based in St. Louis, MO.


Listen to Tom's Story


Additional Solutions for Alcoholism Treatment

Naltrexone/Vivitrol

Naltrexone blocks opioid receptors that are involved in the rewarding effects of drinking and the craving for alcohol. It reduces relapse to heavy drinking, defined as four or more drinks per day for women and five or more for men. Naltrexone cuts relapse risk during the first 3 months by about 36 percent but is less effective in helping patients maintain abstinence. It now comes in a once a month injection called Vivitrol.

Acamprosate

Acamprosate (Campral) acts on the gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems and is thought to reduce symptoms of protracted withdrawal, such as insomnia, anxiety, restlessness, and dysphoria.

Disulfiram (Antabuse)

Disulfiram (Antabuse) interferes with degradation of alcohol, resulting in the accumulation of acetaldehyde, which, in turn, produces a very unpleasant reaction that includes flushing, nausea, and palpitations if the patient drinks alcohol. The utility and effectiveness of disulfiram are considered limited because compliance is generally poor. However, among patients who are highly motivated, disulfiram can be effective, and some patients use it episodically for high-risk situations, such as social occasions where alcohol is present. It can also be administered in a monitored fashion, such as in a clinic or by a spouse, improving its efficacy.

Topiramate

Topiramate is thought to work by increasing inhibitory (GABA) neurotransmission and reducing stimulatory (glutamate) neurotransmission. Its precise mechanism of action in treating alcohol addiction is not known, and it has not yet received FDA approval. Topiramate has been shown in two randomized, controlled trials to significantly improve multiple drinking outcomes, compared with a placebo. Over the course of a 14-week trial, topiramate significantly increased the proportion of patients with 28 consecutive days of abstinence or non-heavy drinking. In both studies, the differences between topiramate and placebo groups were still diverging at the end of the trial, suggesting that the maximum effect may not have yet been reached. Importantly, efficacy was established in volunteers who were drinking upon starting the medication